Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 29681456.
- Also identified by DOI 10.1016/j.cell.2018.03.041 and PMC identifier 6132060.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Triple-negative breast cancer (TNBC) is an aggressive subtype that frequently develops resistance to chemotherapy. An unresolved question is whether resistance is caused by the selection of rare pre-existing clones or alternatively through the acquisition of new genomic aberrations. To investigate this question, we applied single-cell DNA and RNA sequencing in addition to bulk exome sequencing to profile longitudinal samples from 20 TNBC patients during neoadjuvant chemotherapy (NAC). Deep-exome sequencing identified 10 patients in which NAC led to clonal extinction and 10 patients in which clones persisted after treatment. In 8 patients, we performed a more detailed study using single-cell DNA sequencing to analyze 900 cells and single-cell RNA sequencing to analyze 6,862 cells. Our data showed that resistant genotypes were pre-existing and adaptively selected by NAC, while transcriptional profiles were acquired by reprogramming in response to chemotherapy in TNBC patients.
Medical subject headings
- Antineoplastic Agents
- Drug Resistance, Neoplasm
- High-Throughput Nucleotide Sequencing
- Triple Negative Breast Neoplasms